Illumina Inc Stock Price, News & Analysis

Illumina (NASDAQ: ILMN) reported a strong financial performance for 2021, with fourth-quarter revenue at approximately $1.190 billion (+25% YoY) and a full-year revenue of $4.517 billion (+39% YoY). The company anticipates 2022 revenue of $5.15-$5.24 billion, reflecting a growth of 14-16%. CEO Francis deSouza emphasized new partnerships in oncology and advancements in genomic technologies, including early cancer detection tests and innovative sequencing methods. These initiatives aim to enhance healthcare and drive further market penetration.

GRAIL has partnered with the OHSU Knight Cancer Institute to offer the advanced Galleri blood test, which aims to detect over 50 types of cancer early. The pilot program will be available to eligible patients, enhancing cancer detection methods significantly, as traditional screenings only cover a limited number of cancer types. Galleri's low false positive rate and high accuracy in identifying cancer origins are crucial in the fight against cancer, which claims over 600,000 lives annually in the U.S.

GRAIL announced a collaboration with Premier, Inc.'s PINC AI to enhance patient access to Galleri, a multi-cancer early detection blood test. This partnership aims to integrate AI-based alerts for clinicians to identify patients at elevated cancer risk. Community Health Network will pilot these alerts. The Galleri test can detect over 50 cancer types through a single blood draw, improving early detection and treatment outcomes. GRAIL emphasizes the importance of early cancer detection to increase survival rates, as many cancers are diagnosed late when treatment options are limited.

Illumina (NASDAQ: ILMN) has announced a co-development agreement with SomaLogic to integrate the SomaScan® Proteomics Assay with its next-generation sequencing (NGS) platforms. This collaboration aims to enhance the high throughput proteomics market, enabling researchers to analyze thousands of samples for over 10,000 protein targets efficiently and cost-effectively. The partnership taps into the estimated $50 billion proteomics market, allowing Illumina to utilize its extensive NGS technology to boost multiomic research capabilities. Discussions regarding this partnership will take place at the J.P. Morgan Healthcare Conference on January 10, 2022.

Illumina (NASDAQ: ILMN) announced that its executives will present at the J.P. Morgan Annual Healthcare Conference on January 10, 2022. The presentation is set for 12:45 PM PT, followed by a Q&A session starting around 1:05 PM PT. Interested parties can access the live webcast via the Investor Info section on illumina.com. A replay will be available for at least 30 days post-event. Illumina continues to lead in DNA sequencing and array-based technologies, impacting various sectors such as life sciences and clinical markets.

Illumina (NASDAQ: ILMN) partners with Gretel.ai to create privacy-protected synthetic genomic data. This collaboration aims to enhance medical research by providing immediate access to statistically accurate genomic datasets without lengthy approval processes. The partnership demonstrates new use cases for synthetic data in genomics, promising advancements in drug discovery and genetic disorder treatment. With a focus on compliance with GDPR and CCPA, this initiative is poised to accelerate DNA sequencing analysis and medical breakthroughs for various health challenges, including COVID-19.

Illumina (NASDAQ:ILMN) announces support for a national precision medicine study in Norway called IMPRESS-Norway. This initiative aims to evaluate blood-based comprehensive genomic profiling (CGP) for selecting cancer therapies and assess its cost-effectiveness in the public healthcare system. The study will involve a sub-study of 500 patients, comparing solid tissue biopsies with blood samples. If successful, this could make less invasive CGP testing more accessible, enhancing patient participation in clinical trials. The analysis will utilize Illumina's DRAGEN software.

GRAIL, LLC has partnered with Alignment Health Plan to provide Medicare Advantage members in California and North Carolina access to Galleri®, a multi-cancer early detection blood test. Starting January 1, 2022, new and existing members can obtain the test, which detects over 50 cancers, many of which lack standard screenings. The initiative aims to enhance cancer detection among seniors, thereby potentially reducing late-stage diagnoses.

Illumina and Sequoia Capital China announced the first startups joining their Intelligent Healthcare Genomics Incubator in Shanghai, aimed at fostering genomics innovation. The selected companies, Mobidrop Biotechnology and Sequanta Technologies, will benefit from funding, business guidance, and access to Illumina's sequencing systems. This initiative highlights Illumina's commitment to developing China's genomics landscape and supports their localization strategy. Startups will be selected biannually, with applications for the next cycle open until March 1, 2022.